U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H18F3NO3S2
Molecular Weight 453.498
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GW-501516

SMILES

CC1=C(CSC2=CC(C)=C(OCC(O)=O)C=C2)SC(=N1)C3=CC=C(C=C3)C(F)(F)F

InChI

InChIKey=YDBLKRPLXZNVNB-UHFFFAOYSA-N
InChI=1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)

HIDE SMILES / InChI
Molecular Formula C21H18F3NO3S2
Molecular Weight 453.498
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800015062 | https://en.wikipedia.org/wiki/GW501516

GW-501516 is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia, hyperlipidemia, metabolic diseases and cardiovascular diseases. GW501516 treatment is associated with significant improvements in multiple lipid profile components (TG, LDL-C, HDL-C, free fatty acids and apoB, apoA-I and apoA-II) and a shift in LDL particle size from small dense to larger, less dense particles. Despite these promising early results, the further investigation and development of GW501516 was discontinued after observations in animal studies of its association with the rapid induction of cancers in several organs (liver, stomach, tongue, skin, bladder, ovaries, womb and testes).

CNS Activity

CNS Penetrant
2588
Curator's Comment: GW501516 have very poor ability in terms of brain penetration. Known to be CNS penetrant in rodents. Human data not available.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 1.1 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase IV
63
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
REVIEW
https://www.alzdiscovery.org/uploads/cognitive_vitality_media/PPAR%CE%B4_Agonists.pdf
unknown
 GW-501516 plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22814748/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/22814748/
Sources:
https://pubmed.ncbi.nlm.nih.gov/22814748/
PubMed

PubMed

TitleDatePubMed
Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach.
2014-07
In vitro toxicological characterization of perfluorinated carboxylic acids with different carbon chain lengths.
2013-04-12
Role of Peroxisome Proliferator-Activated Receptor β/δ and B-Cell Lymphoma-6 in Regulation of Genes Involved in Metastasis and Migration in Pancreatic Cancer Cells.
2013
Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein.
2012-12-01
A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1α expression and mitochondrial biogenesis.
2012
Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer.
2011-11
GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice.
2011
Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
2011
Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.
2010-09
Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity.
2010-07-15
Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury.
2010-05-05
Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.
2010-02
Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
2009-09
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
2009-08
Regulation of peroxisome proliferator-activated receptor-alpha by MDM2.
2009-03
Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.
2008-11
Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta.
2008-10-24
In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886).
2008-05
The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells.
2007-10-02
Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle.
2007-07-06
Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
2007-06-01
PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle.
2007-03-23
Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
2006-04-24
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
2006-02-28
Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.
2005-11-01
Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms.
2005-10-03
Nanomolar and micromolar effects of 15-deoxy-delta 12,14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B.
2005-07
Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
2005-03
PPAR delta: an uncompletely known nuclear receptor.
2005-02
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
2001-04-24
Patents

Patents

07115611
29
07253192
1
07982050
1

Sample Use Guides

In Vivo Use Guide
12 weeks of treatment with 2.5 mg, 5.0 mg or 5,0 mg, 10 mg
Route of Administration: Oral
In Vitro Use Guide
In 1BR3N human skin fibroblasts, the 1 uM of GW501516 produced a 3.4-fold increase in ABCA1 expression and a 2-fold increase in apoA1-specific cholesterol efflux. In FHS74 human intestinal cells, the 1 uM of GW501516 produced a 2.1-fold increase in ABCA1 expression.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:01:39 GMT 2025
Edited
by admin
on Mon Mar 31 18:01:39 GMT 2025
Record UNII
7I2HA1NU22
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GSK-516
Preferred Name English
GW-501516
Common Name English
CARDARINE
Common Name English
GW-1516
Code English
(2-METHYL-4-(((4-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)-1,3-THIAZOL-5-YL)METHYL)THIO)PHENOXY)ACETIC ACID
Systematic Name English
GW501516
Code English
Classification Tree Code System Code
DSLD 3989 (Number of products:9)
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
DSLD 3986 (Number of products:12)
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
Code System Code Type Description
FDA UNII
7I2HA1NU22
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID3041037
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
PRIMARY
CHEBI
73726
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
PRIMARY
WIKIPEDIA
GW501516
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
PRIMARY
PUBCHEM
9803963
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
PRIMARY
DRUG BANK
DB05416
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
PRIMARY
CAS
317318-70-0
Created by admin on Mon Mar 31 18:01:39 GMT 2025 , Edited by admin on Mon Mar 31 18:01:39 GMT 2025
PRIMARY
Related Record Type Details
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA
TARGET -> AGONIST
Related Record Type Details
Structure of GW-501516
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966